CHRONIC KIDNEY DISEASE IN CHILDREN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 国家糖尿病和消化及肾脏疾病研究所(NIDDK)的肾脏、泌尿外科和血液病学部(DKUHD)与国家神经疾病和中风研究所(NINDS)、国家儿童健康与人类发育研究所(NICHD)和国家心肺和血液研究所(NHLBI)合作，资助了一项合作协议，对慢性肾脏疾病(CKD)儿童进行前瞻性流行病学研究。这项研究的主要目标是确定肾功能下降的危险因素，并确定肾功能进行性下降如何影响神经认知功能和行为；心血管疾病的危险因素；生长障碍及其相关发病率。 具体目标是 确定儿童慢性肾脏病进展的新的和传统的肾脏疾病危险因素(例如，肾小球滤过率下降)， 描述肾功能下降对神经发育、认知能力和行为的影响， 确定在进展性慢性肾脏病中传统的和新的心血管疾病危险因素的流行和演变，以及 研究肾小球滤过率下降对生长的影响和生长障碍的治疗，并评估生长障碍对慢性肾脏病儿童发病率的影响。 本研究将招募患有轻度至中度慢性肾脏病的1至16岁儿童(17岁以前)。约540名儿童将在全国57个不同地点参加这项研究。在辛辛那提儿童医院医疗中心，大约20名儿童将被要求参加这项研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement to conduct a prospective epidemiological study of children with chronic kidney disease (CKD). The primary goals of this study are to determine the risk factors for decline in kidney function and to define how a progressive decline in kidney function impacts neurocognitive function and behavior; the risk factors for cardiovascular disease; and growth failure and its associated morbidity. The specific aims are Identify novel and traditional renal disease risk factors for the progression of CKD (e.g. decline of GFR) in children, Characterize the impact of a decline in kidney function on neurodevelopment, cognitive abilities, and behavior, Identify the prevalence and evolution of traditional and novel cardiovascular disease risk factors in progressive CKD, and Examine the effects of declining GFR on growth and the treatment of growth failure, and to assess the consequences of growth failure on morbidity in children with CKD. Children 1 to 16 years old (before 17th birthday) with mild to moderate CKD will be recruited for this study. About 540 children will be in this study at 57 different sites around the country. About 20 children will be asked to be in this study at Cincinnati Children's Hospital Medical Center.